MedTrace Logo

Screening for Pulmonary Vascular Changes in Patients With Chronic Myeloproliferative Diseases

NCT01787162 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 43

Last updated 2015-09-09

No results posted yet for this study

Summary

Goal of the study is to assess the frequency of pulmonary hypertension in patients with chronic myeloproliferative diseases. In each patient an echocardiography at rest will be performed. In patients without musculoskeletal disease an exercise test (spiroergometry) will be performed. Patients with elevated SPAP at rest or with reduced exercise capacity (peak VO2 \< 65%) a right heart catheterization (RHC) will be recommended. Also patients with advanced NYHA functional class (III or IV) or with typical PH findings in electrocardiogram will be advised to undergo a RHC. Additionally for the evaluation of exercise capacity a 6 MWD will be performed.

This work- up of patients allows clinical and hemodynamic evaluation.

Conditions

  • Myeloproliferative Disorders
  • Pulmonary Hypertension

Interventions

OTHER

Echocardiography, spiroergometry, cardiac catheterization

patients with CMPD will undergo echocardiography, spiroergometry, and right heart catheterization, if indicated

Sponsors & Collaborators

  • Medical University of Graz

    lead OTHER

Principal Investigators

  • Horst Olschewski, MD · Medical University of Graz

Eligibility

Min Age
18 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2015-06-30
Completion
2015-06-30

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01787162 on ClinicalTrials.gov